CsA, is an effective immunsuppressive agent of fungal origin being widely used throughout the world since the beginning of the eighties. Prevention of the rejection attacks as well as graft versus host reactions, a low myelotoxicity and very seldom occurrence of bacterial and fungal infections during the treatment are its leading superior properties. But unfortunately, its potential nephrotoxicity during acute and chronic periods prevents its widespread and confident administration [1]. The damage formed by the use of CsA during the acute period is explained by its negative effect on renal circulation [2].

In experimental studies, it has been shown that the urinary excretion of thromboxane B2, which is a strong vasoconstrictor, increases and the production of PGE2, which is a vasodilator, decreases with the use of CsA [3–6]. In a study conducted in rats, narrowing of afferent arterioles was demonstrated by electron microscopy in kidney biopsies taken from rats given CsA [7]. Accordingly, the toxic effect of CsA is thought to arise as a result of its vasoconstrictive effect [8, 9]. As a result of vasoconstriction, tissue perfusion is impaired at the microcirculation level and adversely affects kidney functions.

Since CsA is metabolized in the liver via the P450 cytochrome enzyme system, it interacts with many drugs that alter this enzyme system. Ketoconazole, cimetidine, erythromycin and corticosteroids increase blood levels of CsA by inhibiting P450 enzyme. Phenytoin, rifampicin, isoniazid, and trimethoprim decrease CsA levels by inducing P450 [10–12].

The nephrotoxic effect of CsA is enhanced when Amphotericin B is co-administered with aminoglycosides, melphalan and Co-trimoxasole [12].

Side effects related to CsA detected in clinical studies are as follows:

a) dose-dependent:
   — renal dysfunction, impaired liver function, hypertension, hypertrichosis, tremor and gingival hyperplasia [12, 13];

b) dose-independent:
   — paraesthesia, nausea, encephalopathy, hyperkalemia, anaemia and susceptibility to infections [12, 13].

In addition, there is no difference between CsA and conventional immunosuppressive therapy in terms of the risk of developing lymphoma and non-lymphoma malignant diseases [13, 14].
CsA toxicity varies with dose, individual susceptibility and certain risk factors. CsA-related lesions:

1) 0–19 % acute renal failure with diffuse interstitial fibrosis;
2) 0–5 % peritubular capillary congestion;
3) 9–37 % tubular toxicity;
4) 5–30 % striped form interstitial fibrosis (interstitial areas of fibrosis in lines and atrophic tubules in these areas);
5) 5–27 % CsA-induced arteriolopathy [13].

Acute renal failure with diffuse interstitial fibrosis can be seen at any time, although peritubular congestion and tubular toxicity are more common in the first months after transplantation. CsA-induced arteriolopathy is usually seen 2 months after transplantation, and striped form interstitial fibrosis 6 months and later [13] (fig. 1).

A) Functional toxicity.
A slight decrease in renal function can be observed in almost all patients with daily administration of 10 mg/kg oral CsA after transplantation. The serum creatinine level is slightly increased. It returns to normal with decreasing the CsA dose [13]. Hypertension develops in half of the patients [15]. CsA is thought to exert a selective vasoconstriction on renal vessels, particularly on arterioles [13]. Its mechanism has been tried to be explained in four ways:

1) direct effect on renal vessels [13];
2) adrenergic system stimulation [16–18];
3) stimulation of the tubuloglomerular feedback mechanism [19, 20];
4) effects on renal prostaglandin synthesis [3, 13].

B) Tubular toxicity.

The findings are not different from those seen in functional nephrotoxicity. But the serum creatinine level is higher, it can be more than twice the normal [13, 15].

Giant mitochondria, isometric vacuolization and microcalcifications are remarkable histopathological findings. These are nonspecific, but rather characteristic lesions [13] (fig. 2).

The main etiological factor in the development of tubular toxicity is high CsA levels. This level is usually above 200 ng/ml [15].

C) Vascular-interstitial toxicity.
The patient has a slow but progressive deterioration in kidney function, resulting in hypertension. Initially, the glomerular filtration rate and renal plasma flow decrease. Then serum creatinine increases; proteinuria is mild or absent. With the discontinuation of CsA, some patients may have an improvement in renal function, but most do not. As a sign of vascular damage, some patients have increased plasma levels of endothelial-derived factor VIII and antithrombin [13, 15].

Renal vasoconstriction is shown as the main cause of CsA-induced nephrotoxicity (fig. 3). For this reason, the first thing that comes to mind for the prevention or treatment of renal toxicity is to reduce the dose of CsA or to replace it with another immunosuppressive. Although FK506-induced nephrotoxicity is observed, it is not as severe as CsA.
as is known. That’s why Tacrolimus seems like an option. The newly introduced co-stimulator blockers are another option. However, the high risk of infection in these should not be ignored.

In a study we conducted on rats, we tried PG12 (prostacyclin) and PGE2, which have vasodilator effects, in this context. In particular, we found that PGE2 significantly reduced vasoconstriction and reduced the toxic effect due to CsA. Our problem here was that we only used these agents once, so we couldn’t continue and only gave them intravenously. However, the results obtained were found to be significant.

References

1. Cohen DJ, Loetscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med. 1984 Nov;101(5):667-682. doi:10.7326/0003-4819-101-5-667.

2. Kahana BD. Cyclosporine. In: Masry SG, Glassock RS, editors. Textbook of Nephrology. 2nd ed. Baltimore: Williams & Wilkins; 1989. 1487-1499 pp.

3. Kawaguchi A, Goldman MH, Shapiro R, Foegh ML, Ramwell PW, Lower RR. Increase in urinary thromboxane B2 in rats caused by cyclosporine. Transplantation. 1985 Aug;40(2):214-216. doi:10.1097/00007890-198508000-00022.

4. Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P. Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function. Transplantation. 1988 May;45(5):883-889. doi:10.1097/00007890-198805000-00008.

5. Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P. Amelioration of experimental cyclosporine nephrotoxicity by calcium channel inhibition. Transplantation. 1992 Dec;54(6):1103-1106.

6. Stahl RA, Kudelka S. Chronic cyclosporine A treatment reduces prostaglandin E2 formation in isolated glomeruli and papilla of rat kidneys. Clin Nephrol. 1986;25(Supp 1):78-82.

7. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 1987 Jul;44(1):135-141. doi:10.1097/00007890-198707000-00027.

8. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8222-8226. doi:10.1073/pnas.82.23.8222.

9. Murray BM, Paller MS. Beneficial effects of renal denervation and prazosin on renal blood flow after cyclosporine in rats. Clin Nephrol. 1986;25(Supp 1):137-143.

10. Dieperink H, Kemp E, Lysesson PP, et al. Ketoconazole and cyclosporine A: combined effects on rat renal function and on serum and tissue cyclosporine A concentration. Clin Nephrol. 1986;25(Supp 1):137-143.

11. Henrisson S, Lindholm A, Aravoglou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol. 1990 Jun;66(1):49-52. doi:10.1111/j.1600-0773.1990.tb0701x.

12. Mihasch MJ, Ryffel B, Gudat F, Thiel G. Cyclosporine nephropathy. In: Tisher CC, Brenner BM, editors. Renal pathology with clinical and functional correlations. 2nd ed. Vol II. Philadelphia: JB Lippincott; 1989. 1555-1586 pp.

13. Hamilton DV, Evans DV, Thura S. Toxicity of cyclosporin A in organ grafting. In: White DJG, editor. Cyclosporin A. Oxford: Elsevier Biomedical Press; 1982. 393-411 pp.

14. Winkelstein A. Immunosuppressive therapy. In: Stites DP, Terr AI, editors. Basic and Clinical Immunology. 7th ed. Connecticut: Appleton and Lange; 1991. 775 p.

15. Mihasch MJ, Thiel G, Ryffel B. Morphologic diagnosis of cyclosporine nephrotoxicity. Semin Diagn Pathol. 1988 Feb;5(1):104-121.

16. Cotran RS, Kumar V, Robbins SL. Diseases of immunity. In: Robbins SL, Cotran RS, Kumar V, editors. Robbins pathologic basis of disease. 4th ed. Philadelphia: WB Saunders; 1989. 163-237 pp.

17. Garr MD, Paller MS. Cyclosporine augments renal but not systemic vascular reactivity. Am J Physiol. 1990 Jan;258(1 Pt 2):F211-217. doi:10.1152/ajprenal.1990.258.1.F211.

18. Owen M. Major histocompatibility complex. In: Roitt IV, Brostoff J, Male DK. Immunology. 2nd ed. New York: Gower Medical Publishing; 1989. 4.1-4.11 pp.

19. Mihasch MJ, Morozumi K, Ryffel B, Thiel G. Old and new aspects of cyclosporine nephropathy. In: Leiman G, editor. XIX international congress of the international academy of pathology. 1992, October 18-23; Madrid, Spain. doi:10.1002/dec.2840080426.

20. Schachter M. Cyclosporine A and hypertension. J Hypertens. 1988 Jul;6(7):511-516. doi:10.1097/00004872-198807000-00001.

Received 25.09.2021
Revised 02.10.2021
Accepted 10.10.2021
Циклоспоринова нефропатія, її патогенез і лікування

Резюме. Циклоспорин А, отриманий із гриба під назвою Tolypocladium inflatum, почав застосовуватися в медичні в 1983 році. З початком застосування циклоспорину продемонстровано підвищення 3- та 5-річного виживання транспланта. Однак нефротоксичність, виявлена в ранній та пізній період, ускладнює його застосування. Дуже важливо відрізняти ранню токсичність від нападів відторгнення, що пов’язано з абсолютно різними методами лікування обох процесів. Хоча вазоконстрикція в системі ниркових артерій проявляється в ранньому періоді, основним фактором пізнії токсичності є пониження артеріольної інтраті, як наслідок, зменшення оксигенации тканин. У статті розглянуті варіанти токсичності, зумовлені використанням циклоспорину А. На моделях шу- рів показані морфологічні зміни при використанні циклоспорину А. Також наведені результати власних спостережень щодо використання протестуанів, який продемонстрував ефект вазодилатації, що, ймовірно, можна використовувати для подальших досліджень з метою зменшення нефротоксичності циклоспорину А. Зокрема, ми виявили, що PGE2 значно зменшує звуження судин і знижує токсичний ефект, обумовлений циклоспорином А. Обмеженням було одноразо- ве використання цих засобів, тому ми не могли продовжувати дослідження та вводили їх тільки внутрішньовенно. Однак отримані результати виявилися обнадійливими.

Ключові слова: трансплантація; токсичність циклоспорину А; вазоконстрикція артеріол нирок; нефротоксичність

Циклоспориновая нефропатия, ее патогенез и лечение

Резюме. Циклоспорин А, полученный из грибка под названием Tolypocladium inflatum, стал использоваться в медицине в 1983 году. С началом применения циклоспорина продемонстрировано повышение 3- и 5-летней выживаемости трансплантата. Однако нефротоксичность, наблюдаемая в раннем и позднем периодах, затрудняет его использование. Очень важно отличать раннюю токсичность от приступов отторжения, что связано с совершенно разными методами лечения обоих процессов. Хотя вазоконстрикция в системе почечных артерий проявляется в раннем периоде, основным фактором поздней токсичности является утолщение интимы артериол и, как следствие, снижение оксигенации тканей. В статье рассмотрены варианты токсичности, обусловленные использованием циклоспорина А. На моделях крыс показаны морфологические изменения при использовании циклоспорина А. Также приведены результаты собственных наблюдений по использованию протестуанта, который продемонстрировал эффект вазодилатации, что, вероятно, можно применять для дальнейших исследований с целью уменьшения нефротоксичности циклоспорина А. В частности, мы обнаружили, что PGE2 значительно уменьшает сужение сосудов и снижает токсический эффект, вызванный циклоспорином А. Ограничением было однократное использование этих препаратов, поэтому мы не могли продолжать исследование и вводили их только внутривенно. Однако полученные результаты оказались обнадеживающими.

Ключевые слова: трансплантация; токсичность, обусловленная циклоспорином А; вазоконстрикция почечных артериол; нефротоксичность